Patient‐derived xenografts for individualized care in advanced sarcoma. Issue 13 (4th April 2014)

• Record Type: Journal Article
• Authors: Stebbing, Justin; Paz, Keren; Schwartz, Gary K.; Wexler, Leonard H.; Maki, Robert; Pollock, Raphael E.; Morris, Ronnie; Cohen, Richard; Shankar, Arjun; Blackman, Glen; Harding, Victoria; Vasquez, David; Krell, Jonathan; Ciznadija, Daniel; Katz, Amanda; Sidransky, David
• Is Part Of: Cancer. Volume 120:Issue 13(2014)
• Page Start: 2006
• Page End: 2015
• Publication Date: 2014-04-04
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.28696
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr28696-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard‐of‐care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in conducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient‐derived xenografts using a proprietary method ("TumorGrafts").</p> </sec> <sec id="cncr28696-sec-0002" sec-type="section"> <title>METHODS</title> <p>Tumors resected from 29 patients with sarcoma were implanted into immunodeficient mice to identify drug targets and drugs for clinical use. The results of drug sensitivity testing in the TumorGrafts were used to personalize cancer treatment.</p> </sec> <sec id="cncr28696-sec-0003" sec-type="section"> <title>RESULTS</title> <p>Of 29 implanted tumors, 22 (76%) successfully engrafted, permitting the identification of treatment regimens for these patients. Although 6 patients died before the completion of TumorGraft testing, a correlation between TumorGraft results and clinical outcome was observed in 13 of 16 (81%) of the remaining individuals. No patients progressed during the TumorGraft‐predicted therapy.</p> </sec> <sec id="cncr28696-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>The current data support the use of the personalized TumorGraft model as an investigational platform for therapeutic decision‐making that can guide treatment for rare tumors such as sarcomas. A randomized phase 3 trial versus physician's choice is warranted. <bold><italic>Cancer</italic> 2014;120:2006–2015</bold>. © 2014 The Authors. <italic>Cancer</italic> published by Wiley Periodicals, Inc. on behalf of <italic>American Cancer Society</italic>.</p> </sec> </abstract>